Delving into the Latest Updates on Frosst Ibérica SA with Synapse

Overview

Tags

Nervous System Diseases

Congenital Disorders

Skin and Musculoskeletal Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

DAG1(Dystroglycan)	1

本研究的主要目的是通过六分钟步行试验（6MWT）评估确定Ataluren 对行走和耐力的影响。本研究的次要目的为，通过计时功能测试评估确定Ataluren 对行走和爆发式活动的影响；通过北极星移动评价量表（NSAA）评估确定Ataluren 对下肢肌肉功能的影响；评价Ataluren 的安全性特征。

[Translation]

The primary objective of this study was to determine the effects of Ataluren on walking and endurance as assessed by the Six-Minute Walk Test (6MWT). Secondary objectives of this study were to determine the effects of Ataluren on walking and burst activity as assessed by the Timed Functional Test; to determine the effects of Ataluren on lower extremity muscle function as assessed by the North Star Ambulatory Assessment (NSAA); and to evaluate the safety profile of Ataluren.

Start Date05 Dec 2018

Sponsor / Collaborator

PTC Therapeutics, Inc.

[+2]

100 Clinical Results associated with Frosst Ibérica SA

Login to view more data

0 Patents (Medical) associated with Frosst Ibérica SA

Login to view more data

100 Deals associated with Frosst Ibérica SA

Login to view more data

100 Translational Medicine associated with Frosst Ibérica SA

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data